Australia and New Zealand Healthcare CROs Market Report and Forecast 2024-2032

Australia and New Zealand Healthcare CROs Market Report and Forecast 2024-2032


Australia and New Zealand Healthcare CROs Market Outlook

The Australia and New Zealand healthcare CROs market size was valued USD 1.1 billion in 2023, driven by increasing complexity of clinical trials, rising R&D costs, the need for specialized expertise, and the focus on accelerating drug development. The market size is anticipated to grow at a CAGR of 11.9% during the forecast period of 2024-2032 to achieve a value of USD 3.0 billion by 2032.

Australia and New Zealand Healthcare CROs: Introduction

The healthcare Contract Research Organizations (CROs) market in Australia and New Zealand refers to the segment of the clinical research industry that provides outsourced services to pharmaceutical, biotechnology, and medical device companies in these countries. CROs play a crucial role in conducting clinical trials and providing various research and development services to support the development of new drugs, therapies, and medical devices.

Healthcare CROs in Australia and New Zealand offer a wide range of services to support the entire clinical trial process. These services include protocol development, site selection and management, patient recruitment, data management and analysis, regulatory submissions, safety monitoring, and quality assurance. CROs assist in streamlining the clinical trial process, ensuring compliance with regulatory requirements, and providing expertise and resources to efficiently conduct trials.

Key Trends in the Australia and New Zealand Healthcare CROs Market

Key Trends in the Australia and New Zealand healthcare CROs market:
  • Increasing Outsourcing of Clinical Research: Pharmaceutical and biotechnology companies in Australia and New Zealand are increasingly outsourcing their clinical research activities to CROs. This trend is driven by the need for specialized expertise, cost-efficiency, and the ability to access a global network of investigators and patients.
  • Growing Demand for Oncology Trials: Oncology clinical trials have witnessed significant growth in Australia and New Zealand. There is a rising demand for CROs specializing in oncology research due to the increasing prevalence of cancer and advancements in personalized medicine.
  • Emphasis on Patient-Centric Approach: There is a growing emphasis on patient-centricity in clinical trials, and CROs are adopting strategies to enhance patient recruitment, engagement, and retention. CROs are leveraging technology, such as mobile applications and virtual visits, to improve patient experience and reduce the burden of participation.
  • Digital Transformation and Data Analytics: The healthcare CROs market is undergoing digital transformation, with the adoption of technologies like electronic data capture (EDC), electronic patient-reported outcomes (ePRO), wearables, and data analytics. These technologies enable real-time data collection, remote monitoring, and advanced analytics, enhancing the efficiency and accuracy of clinical trials.
  • Regulatory Compliance and Quality Assurance: The regulatory landscape for clinical trials is evolving, necessitating CROs to ensure compliance with stringent regulatory requirements. CROs in Australia and New Zealand are focusing on quality assurance and implementing robust systems and processes to maintain compliance with regulatory guidelines.
Australia and New Zealand Healthcare CROs Market Segmentation

The market can be categorised into phase type, and indication.

Market Breakup by Phase Type
  • Drug Discovery
  • Preclinical
  • Clinical
Market Breakup by Indication
  • Oncology
  • Cardiovascular
  • Autoimmune/Inflammation
  • Central Nervous System (CNS)
  • Dermatology
  • Infectious Diseases
  • Respiratory
  • Others
Australia and New Zealand Healthcare CROs Market Overview

The healthcare CROs market in Australia and New Zealand has experienced significant growth in recent years. Factors contributing to market growth include the increasing complexity of clinical trials, rising R&D costs, the need for specialized expertise, and the focus on accelerating drug development.

The healthcare CROs market in Australia and New Zealand is competitive, with both local and international players operating in the region. Key market players include large multinational CROs, mid-size CROs, and niche specialty CROs. These CROs compete based on their therapeutic expertise, quality of services, geographical reach, and technological capabilities. The healthcare CROs market in Australia and New Zealand is expected to continue growing in the coming years. Factors such as the increasing focus on personalized medicine, advancements in digital health technologies, the need for efficient drug development processes, and the growing demand for real-world evidence (RWE) are expected to drive market growth. CROs that can adapt.

Key Players in the Australia and New Zealand Healthcare CROs Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in Australia and New Zealand healthcare CROs market are as follows:
  • PAREXEL International Corporation
  • Thermo SGS SA
  • ICON plc
  • Medpace Australia Pty. Ltd
  • Charles River Laboratories International, Inc.
  • IQVIA
  • Novotech
  • Laboratory Corporation of America Holdings
  • Syneos Health
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand Healthcare CROs Market Overview
3.1 Australia and New Zealand Healthcare CROs Market Historical Value (2017-2023)
3.2 Australia and New Zealand Healthcare CROs Market Forecast Value (2024-2032)
4 Australia and New Zealand Healthcare CROs Market Landscape
4.1 Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Australia and New Zealand Healthcare CROs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Australia and New Zealand Healthcare CROs Market Segmentation
6.1 Australia and New Zealand Healthcare CROs Market by Phase Type
6.1.1 Market Overview
6.1.2 Drug Discovery
6.1.3 Preclinical
6.1.4 Clinical
6.2 Australia and New Zealand Healthcare CROs Market by Indication
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiovascular
6.2.4 Autoimmune/Inflammation
6.2.5 Central Nervous System (CNS)
6.2.6 Dermatology
6.2.7 Infectious Diseases
6.2.8 Respiratory
6.2.9 Others
7 Australia and New Zealand Healthcare CROs Market
7.1 Market Share by Country
7.2 Australia
7.3 New Zealand
8 Funding and Investment Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Supplier Landscape
10.1 PAREXEL International Corporation
10.1.1 Financial Analysis
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Thermo Fischer Scientific, Inc.
10.2.1 Financial Analysis
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 SGS SA
10.3.1 Financial Analysis
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 ICON plc
10.4.1 Financial Analysis
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 Medpace Australia Pty. Ltd
10.5.1 Financial Analysis
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Charles River Laboratories International, Inc.
10.6.1 Financial Analysis
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 IQVIA
10.7.1 Financial Analysis
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Novotech
10.8.1 Financial Analysis
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Laboratory Corporation of America Holdings
10.9.1 Financial Analysis
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Syneos Health
10.10.1 Financial Analysis
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
11 Key Opinion Leaders (KOL) Insights (Additional Insight)
12 Company Competitiveness Analysis (Additional Insight)
12.1 Very Small Companies
12.2 Small Companies
12.3 Mid-Sized Companies
12.4 Large Companies
12.5 Very Large Companies
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings